Bioversys AG (SW:BIOV) — Market Cap & Net Worth
Market Cap & Net Worth: Bioversys AG (BIOV)
Bioversys AG (SW:BIOV) has a market capitalization of $160.82 Million (CHF127.20 Million) as of September 19, 2026. Listed on the SW stock exchange, this Switzerland-based company holds position #17466 globally and #177 in its home market, demonstrating a 7.92% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bioversys AG's stock price CHF28.60 by its total outstanding shares 5848011 (5.85 Million). Also see BIOV current and non-current assets for a full breakdown of the balance sheet.
Bioversys AG Market Cap History: 2025 to 2026
Bioversys AG's market capitalization history from 2025 to 2026. Data shows change from $180.40 Million to $211.45 Million (-9.37% CAGR). Also see Bioversys AG operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Bioversys AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bioversys AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Bioversys AG for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
225.50x
Bioversys AG's market cap is 225.50 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $180.40 Million | $800.00K | -$21.83 Million | 225.50x | N/A |
Competitor Companies of BIOV by Market Capitalization
Companies near Bioversys AG in the global market cap rankings as of September 19, 2026. Review Bioversys AG tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Bioversys AG by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
Bioversys AG Historical Marketcap From 2025 to 2026
Between 2025 and today, Bioversys AG's market cap moved from $180.40 Million to $ 211.45 Million, with a yearly change of -9.37%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CHF211.45 Million | +17.21% |
| 2025 | CHF180.40 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Bioversys AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $160.82 Million USD |
| MoneyControl | $160.82 Million USD |
| MarketWatch | $160.82 Million USD |
| marketcap.company | $160.82 Million USD |
| Reuters | $160.82 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bioversys AG
BioVersys AG researches and develops antimicrobial drugs for bacterial infections. It develops BV100 that is in Phase 3 clinical trial for carbapenem-resistant Acinetobacter baumannii lung and bloodstream infections. The company is also developing Alpibectir, which is in Phase 2 clinical trial for the treatment of pulmonary and meningeal tuberculosis; BV200 to treat patients with Gram-positive S.… Read more